Liftstream is an executive search recruitment company in the life sciences sector
Michael O’Neill is a Biotech entrepreneur, currently R&D Director of his own company Inflection Biosciences. He is also a chartered psychologist and has worked as a consultant and technical and organisational issues in the biosciences industry for many years. He is co-editor of the book “A Biotech Manager’s Handbook”, which is a practical guide to some key areas of managing bioscience companies. In this article, he offers some thoughts on how leaders set the tone for the organisational style of their companies and in particular how they manage conflict within the company.
Michael O’Neill is a Biotech entrepreneur, currently R&D Director of his own company Inflection Biosciences. He is also a chartered psychologist and has worked as a consultant and technical and organisational issues in the biosciences industry for many years. He is co-editor of the book “A Biotech Manager’s Handbook”, which is a practical guide to some key areas of managing bioscience companies.
Sorrento Therapeutics, clinical-stage biopharmaceutical company in San Diego, and Yuhan Corporation, an established health care company based in Seoul, have entered into an agreement to form a joint venture, ImmuneOncia Therapeutics. The joint venture will develop and commercialise a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.
BOSTON & CAMBRIDGE, Massachusetts – Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics have announced that the two companies have entered into a strategic research collaboration focused on the use of CRISPR’s gene editing technology, known as CRISPR-Cas9, to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. The collaboration will evaluate the use of CRISPR-Cas9 across multiple diseases where targets have been validated through human genetics. Vertex and CRISPR will focus their initial gene editing research on discovering treatments to address the mutations and genes known to cause and contribute to cystic fibrosis and sickle cell disease. Vertex and CRISPR will also evaluate a specified number of other genetic targets as part of the collaboration. Vertex will have exclusive rights to license up to six new CRISPR-Cas9-based treatments that emerge from the collaboration. As part of the collaboration, Vertex made an up-front commitment of $105 million to CRISPR, including $75 million in cash and a $30 million equity investment. CRISPR is also eligible to receive future development, regulatory and sales milestones and royalty payments on future sales.
Valeant Pharmaceuticals is a very aggressive acquirer of companies and assets. The Canadian company has most recently purchased the rights to an asset from AstraZeneca in the area of psoriasis. The drug, brodalumab, was previously partnered with Amgen but the company exited the agreement from AstraZeneca earlier this year upon concerns of suicidal thoughts in patients enrolled in trials, allowing AZ to find a new partner for the late-stage asset.
MorphoSys based out of Munich and G7 Therapeutics AG of Zurich announced today that they have signed an agreement to collaborate on novel antibody therapeutics targeting G protein-coupled receptors (GPCRs) and potentially other disease-related transmembrane proteins such as ion channels. Under the terms of the agreement, G7 Therapeutics will generate a set of disease-relevant receptors proposed by MorphoSys. MorphoSys will then apply its proprietary Ylanthia antibody library to discover and develop antibody therapeutics against these receptors. MorphoSys has the right to sublicense to third parties the access to these targets in conjunction with therapeutic antibody candidates.Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG, commented: “G7 Therapeutics’ approach using directed evolution technologies broadens our existing development capabilities in this innovative area of research. High quality therapeutic antibodies targeting GPCRs and other transmembrane molecules represent a promising addition to our proprietary development pipeline.”